The emerging Zika virus is a particular threat to pregnant women. The disease can be transmitted by the bite of an infected mosquito and is associated with devastating birth defects, like microcephaly. No approved vaccine against the virus exists.
The Department of Defense is trying to speed up the process of finding an effective vaccine, particularly for pregnant women. As part of a program called the Congressionally Directed Medical Research Program, the DOD is awarding Texas Biomedical Research Institute $2 million over the next three years to study a promising experimental Zika vaccine.
“If there’s something we can do to intervene for a pregnant woman and her fetus who are at risk, it’s certainly something we want to be looking at. I think most of the work being done now is focused on how we intervene during pregnancy since that is where the risk is,” explained Professor Jean Patterson, PhD, a principal investigator (PI) on the study. She describes a “sense of urgency” in the medical community to come up with a way to protect this vulnerable population.
The DOD supports research on many different tropical diseases and is particularly interested in Zika, as pregnant service members may get sent to areas of the world where Zika is endemic.
Texas Biomed’s partner in the project is Marcia Blackman, PhD, of Trudeau Institute in New York who is also serving as PI.
Marmosets housed at the Southwest National Primate Research Center on the Texas Biomed campus will serve as animal models for the study. According to Patterson, these small nonhuman primates work well for Zika research since they breed year round and often have twins or triplets.
“We know a lot about the reproductive cycle of the marmoset and, in particular, the placenta,” Patterson added.
At Trudeau Institute, researchers will work with a mouse model.
Human safety testing is underway on a formalin inactivated vaccine developed at Walter Reed Army Institute of Research. An inactivated vaccine, as opposed to a live vaccine, consists of virus particles that have been grown in culture and then killed with a chemical. The inactivated vaccine still creates an immune response.
However, that study is just one aspect of the ongoing research. Animal testing is critical to gauge the effectiveness of the vaccine. Both the vaccine itself and blood taken from the human subjects who have developed antibodies to Zika will be tested in the animal models.
The animal testing has two goals. First, scientists will look at the possibility that pregnant animals could be vaccinated before being exposed to Zika and be protected from ever getting the virus. Second, using the transfer of antibodies from humans who have received the experimental vaccine, scientists will see if this method could protect already pregnant animals from passing the virus to the fetus in the womb.
Zika is a flavivirus â the same category as other vector-borne illnesses like West Nile, dengue and yellow fever. Other researchers around the world are trying to develop Zika vaccines using different platforms like DNA vaccines, live attenuated vaccines and adeno-associated virus vaccines.
The Zika vaccine research project dovetails with Texas Biomed’s mission to eradicate the threat of infectious diseases and protect global human health.
This work is supported by Department of Defense grant # W81XWH1920020.
Source: Texas Biomed
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.